Friday, 29/08/2008
ABT-874
| Partners | Product | Target | Disease | PreC | PhI | PhII | PhIII | Fld | Mkt |
|---|---|---|---|---|---|---|---|---|---|
| Abbott | ABT-874 | IL-12 | Crohn's disease | ||||||
| Abbott | ABT-874 | IL-12 | psoriasis |
ABT-874 is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. ABT-874 was isolated and optimised by CAT in collaboration with Abbott with Abbott responsible for its further development and marketing.
IL-12 or Interleukin 12 is a biological molecule found in the human body, responsible for triggering inflammation in a number of severe autoimmune and inflammatory disorders.
Abbott is evaluating ABT-874 for autoimmune diseases including Crohn's disease and psoriasis. Initial results from a Phase II study in Crohn's disease suggest that ABT-874 showed significant response and remission rates in patents with active Crohn's disease compared to placebo in one arm of the study.
ABT-874 showed significant efficacy versus placebo in a Phase II study in psoriasis. Abbott plans to initiate Phase IIb and Phase III trials in Crohn's disease and psoriasis, respectively, in 2007. The treatment will not be progressed for multiple sclerosis.
In 2007 ABT-874 entered Phase III trials in patients with psoriasis.